A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs LY 3000328 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 14 Apr 2014 New trial record